New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 18, 2013
07:39 EDTCYTKCytokinetics completes patient enrollment in third cohort of AROMIC-AHF
Cytokinetics announced that ATOMIC-AHF has completed patient enrollment in its third and final cohort. ATOMIC-AHF, or Acute Treatment with Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure, is a Phase IIb clinical trial designed to evaluate the safety, tolerability and efficacy of an intravenous formulation of omecamtiv mecarbil compared to placebo in patients with left ventricular systolic dysfunction who are hospitalized with acute heart failure. Cytokinetics expects results from ATOMIC-AHF will be announced in mid-year 2013. Cytokinetics also announced that dosing of patients has initiated in COSMIC-HF, or Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure. COSMIC-HF is a Phase II clinical trial designed to evaluate the pharmacokinetics, safety and efficacy of oral modified release formulations of omecamtiv mecarbil, in patients with chronic, stable heart failure and left ventricular systolic dysfunction.
News For CYTK From The Last 14 Days
Check below for free stories on CYTK the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 16, 2014
14:33 EDTCYTKCytokinetics volatility elevated into trial data announcement
Cytokinetics May call option implied volatility is at 279, August is at 180, November is at 140; compared to its 26-week average of 158 according to Track Data, suggesting larger near term price movement into the tirasemtiv Phase IIb trial data likely to be announced at the American Academy of Neurology meeting in late April.
April 11, 2014
10:56 EDTCYTKOptions with increasing implied volatility: CYTK VJET DATA GRPN CTRP
April 10, 2014
11:23 EDTCYTKOptions with increasing implied volatility: CYTK BX
Subscribe for More Information
April 9, 2014
11:45 EDTCYTKOptions with increasing implied volatility: CYTK NSR NOW ETFC PBR
08:30 EDTCYTKSummer Street's chief scientific officer holds analyst/industry conference call
Chief Scientific Officer Classen discusses Cytokinetics' (CYTK) Tirasemtiv for treatment of Amyotrophic Lateral Sclerosis (ALS) on an Analyst/Industry conference call to be held on April 9 at 11 am.
April 8, 2014
11:22 EDTCYTKOptions with increasing implied volatility: CYTK NSR NOW ETFC SPLK
Subscribe for More Information
09:08 EDTCYTKCytokinetics volatility elevated into trial data announcement
Subscribe for More Information
April 7, 2014
17:02 EDTCYTKSAC Capital reports 5.5% passive stake in Cytokinetics
11:37 EDTCYTKOptions with increasing implied volatility: CYTK NSR NOW ETFC LF
Subscribe for More Information
April 4, 2014
11:16 EDTCYTKOptions with decreasing implied volatility: MNKD GALT CYTK DLLR APOL
April 3, 2014
11:24 EDTCYTKOptions with decreasing implied volatility: MNKD GALT CYTK DLLR

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use